2μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Insulin-like growth factor-binding protein 2; IBP-2; IGF-binding protein 2; IGFBP-2; |
| Accession | P18065 |
| Amino Acid Sequence | Glu37-Gln325 |
| Expression System | CHO |
| Molecular Weight | 33 kDa (Reducing) |
| Purity | >95% by SDS-PAGE and HPLC. |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | ·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Oncogene. 2020 Mar;39(11):2243-2257. |
Background
IGFBP-2, or insulin-like growth factor binding protein 2, is a member of the high-affinity binding protein family (IGFBP1-6) and plays a significant role in the regulation of insulin-like growth factors (IGFs) in the central nervous system. This protein is part of a family of six similar proteins that bind to IGF-I and IGF-II, influencing their bioavailability and activity in metabolic signaling. IGFBP-2 can be secreted into the bloodstream, where it binds IGF-I and IGF-II with high affinity, or it can remain intracellular, interacting with various ligands. High expression levels of IGFBP-2 are associated with the growth of several types of tumors and may predict patient recovery chances.
In the biotechnology and pharmaceutical industries, IGFBP-2 is of significant interest due to its implications in various diseases and conditions. The protein's role in tumor growth makes it a potential biomarker and therapeutic target for cancer research. Elevated levels of IGFBP-2 during the progression of many human cancers suggest its importance in oncology.
Additionally, IGFBP-2's involvement in metabolic signaling pathways positions it as a key player in the study and treatment of obesity, diabetes, and other metabolic diseases.
Picture
Picture
SDS-PAGE
SEC-HPLC
>95% as determined by SEC-HPLC.
